{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:00:25Z","timestamp":1790060425650,"version":"4.0.1"},"reference-count":112,"publisher":"Elsevier","isbn-type":[{"value":"9780128165751","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.03.006","type":"book-chapter","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T13:38:34Z","timestamp":1553261914000},"page":"189-216","source":"Crossref","is-referenced-by-count":47,"title":["Immunotherapy of pancreatic cancer"],"prefix":"10.1016","author":[{"given":"Yoshiaki","family":"Sunami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kleeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2019.03.006_bb0010","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0015","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0020","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/bs.pmbts.2019.03.006_bb0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.03.006_bb0030","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"10073","key":"10.1016\/bs.pmbts.2019.03.006_bb0035","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/bs.pmbts.2019.03.006_bb0040","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0050","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5023","key":"10.1016\/bs.pmbts.2019.03.006_bb0055","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","article-title":"Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications","volume":"1","author":"Burnet","year":"1957","journal-title":"Br Med J"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0065","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0070","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.49.2.251","article-title":"Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis","volume":"49","author":"Detjen","year":"2001","journal-title":"Gut"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nri3799","article-title":"Balancing natural killer cell activation through paired receptors","volume":"15","author":"Martinet","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/bjc.1984.168","article-title":"Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas","volume":"50","author":"Funa","year":"1984","journal-title":"Br J Cancer"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0090","doi-asserted-by":"crossref","first-page":"66586","DOI":"10.18632\/oncotarget.11953","article-title":"Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0095","first-page":"135","article-title":"Velcade (Bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0100","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1158\/0008-5472.CAN-05-2370","article-title":"Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0105","doi-asserted-by":"crossref","first-page":"56968","DOI":"10.18632\/oncotarget.18185","article-title":"Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells","volume":"8","author":"Van Audenaerde","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.03.006_bb0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nri.2016.116","article-title":"Dendritic cell migration in health and disease","volume":"17","author":"Worbs","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0120","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41467-018-03600-6","article-title":"Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance","volume":"9","author":"Meyer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0125","first-page":"6445","article-title":"Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines","volume":"61","author":"Schnurr","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-017-0459-2","article-title":"Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer","volume":"10","author":"Mehrotra","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0135","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/gut.2006.108621","article-title":"Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model","volume":"56","author":"Bauer","year":"2007","journal-title":"Gut"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0140","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.18632\/oncotarget.22974","article-title":"Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I\/II trial","volume":"9","author":"Hirooka","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0145","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6600986","article-title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0160","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0165","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0170","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ni.1835","article-title":"CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms","volume":"11","author":"Ise","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.13625","article-title":"Regulatory T cells: a potential target in cancer immunotherapy","volume":"1417","author":"Shitara","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0190","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0200","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0215","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0220","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J Biomed Sci"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0230","doi-asserted-by":"crossref","first-page":"6940546","DOI":"10.1155\/2017\/6940546","article-title":"A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma","volume":"2017","author":"Hsu","year":"2017","journal-title":"J Immunol Res"},{"issue":"Suppl 2","key":"10.1016\/bs.pmbts.2019.03.006_bb0235","article-title":"INT230-6 shows strong synergy with anti-PD-1 and can induce high complete response rates with T cell memory response in a colon cancer mouse model","volume":"3","author":"Bloom","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0240","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0245","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0250","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0255","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-18-1325","article-title":"A phase I\/II study of evofosfamide, a hypoxia-activated prodrug with or without bortezomib in subjects with relapsed\/refractory multiple myeloma","volume":"25","author":"Laubach","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0260","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0265","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0270","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0280","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.coi.2013.01.006","article-title":"Inflammatory networks and immune surveillance of pancreatic carcinoma","volume":"25","author":"Vonderheide","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0285","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.09.037","article-title":"Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer","volume":"279","author":"Clark","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0295","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","article-title":"Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer","volume":"66","author":"Zhang","year":"2017","journal-title":"Gut"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0300","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.immuni.2017.07.014","article-title":"Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression","volume":"47","author":"Zhu","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0310","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.03.006_bb0315","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0320","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0325","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0330","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0335","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","article-title":"CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype","volume":"23","author":"Candido","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0340","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","article-title":"Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4\/80(+) extratumoral macrophages","volume":"149","author":"Beatty","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0345","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0350","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrd.2018.149","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0355","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1084\/jem.20161707","article-title":"NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma","volume":"214","author":"Daley","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0360","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0365","doi-asserted-by":"crossref","first-page":"8618","DOI":"10.1038\/s41598-018-26775-w","article-title":"MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice","volume":"8","author":"Perera","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0370","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrm3683","article-title":"Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death","volume":"14","author":"Ofengeim","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0375","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2018.10.006","article-title":"RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer","volume":"34","author":"Wang","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0380","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm.4314","article-title":"Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance","volume":"23","author":"Daley","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0385","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nri1745","article-title":"Dectin-1: a signalling non-TLR pattern-recognition receptor","volume":"6","author":"Brown","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0390","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature10071","article-title":"Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'","volume":"472","author":"Goodridge","year":"2011","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0395","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1084\/jem.20132349","article-title":"CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity","volume":"211","author":"Jia","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0400","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0405","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0410","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-11-0261","article-title":"Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment","volume":"10","author":"Stokes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0415","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0420","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MPA.0b013e31816618ce","article-title":"Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma","volume":"37","author":"Cohen","year":"2008","journal-title":"Pancreas"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0425","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0430","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0435","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0440","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.pharmthera.2017.05.012","article-title":"Emerging roles of the CXCL12\/CXCR4 axis in pancreatic cancer progression and therapy","volume":"179","author":"Sleightholm","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0445","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0450","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0455","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0460","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","article-title":"The potential of CAR T cell therapy in pancreatic cancer","volume":"9","author":"Akce","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0465","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","article-title":"Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps","volume":"166","author":"Beatty","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0470","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0475","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0480","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","article-title":"Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma","volume":"40","author":"Einama","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0485","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/1541-7786.MCR-16-0296","article-title":"Oncogenic KRAS targets MUC16\/CA125 in pancreatic ductal adenocarcinoma","volume":"15","author":"Liang","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0490","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0495","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000079824","article-title":"Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades","volume":"4","author":"Jacob","year":"2004","journal-title":"Pancreatology"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0500","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0505","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1053\/j.gastro.2012.07.017","article-title":"Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice","volume":"143","author":"Maliar","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0510","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/1568009043332916","article-title":"Carcinoembryonic antigen as a target to induce anti-tumor immune responses","volume":"4","author":"Sarobe","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0515","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/j.gastro.2012.06.037","article-title":"T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice","volume":"143","author":"Chmielewski","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0520","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0525","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1349-7006.2009.01176.x","article-title":"HER2 overexpression correlates with survival after curative resection of pancreatic cancer","volume":"100","author":"Komoto","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0530","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0535","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0540","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0545","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0550","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0555","article-title":"Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma","author":"Raj","year":"2018","journal-title":"Gut"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0560","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(92)90030-G","article-title":"RAG-1-deficient mice have no mature B and T lymphocytes","volume":"68","author":"Mombaerts","year":"1992","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2019.03.006_bb0565","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J Exp Med"}],"container-title":["Progress in Molecular Biology and Translational Science","Cancer Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T21:11:10Z","timestamp":1606943470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117319300407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128165751"],"references-count":112,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.03.006","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}